Fangyuan Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fangyuan Cao has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Frank Jacobus Dekker
Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, Groningen 9713 AV, The Netherlands
1 shared publication - Martijn R. H. Zwinderman
Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9713 AV Groningen, The Netherlands
1 shared publication
Latest Publications
- 5 February 2021
- Published by University of Groningen Press
Novel Approaches for Developing Small Molecules to Target Histone Deacetylases
- 5 February 2021
- Published by University of Groningen Press
Novel Approaches for Developing Small Molecules to Target Histone Deacetylases
- Open Access
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.
Open AccessThe Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.